本文選題：潰瘍性結(jié)腸炎 + 緩解期��； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的:評(píng)估補(bǔ)脾益腸丸在潰瘍性結(jié)腸炎中的治療效果以及安全性,為其在潰瘍性結(jié)腸炎中的使用奠定理論基礎(chǔ)。方法:選取2015年1月~2016年9月在濰坊市市立醫(yī)院、濰坊市第二人民醫(yī)院診治的118例潰瘍性結(jié)腸炎患者展開研究,入組標(biāo)準(zhǔn)為:符合西醫(yī)診斷標(biāo)準(zhǔn)無發(fā)熱及需要治療的腸外癥狀和全身癥狀者,且病變侵及乙狀結(jié)腸以上者,除外服用其他疾病的藥物有可能影響研究結(jié)果者;按中醫(yī)診斷標(biāo)準(zhǔn)除外熱毒熾盛型患者,所有患者按照就診順序隨機(jī)編號(hào)為1-118號(hào),奇數(shù)號(hào)者為治療組,偶數(shù)號(hào)者為對照組。其中治療組和對照組各59例。對照組患者采用始終應(yīng)用5氨基水楊酸治療;治療組在對照組基礎(chǔ)上急性癥狀緩解后(中醫(yī)證候積分小于等于2分)加用補(bǔ)脾益腸丸治療,2個(gè)月為1個(gè)療程,完成2個(gè)療程的治療后通過比較兩組治療前后證候療效,腸鏡下粘膜表現(xiàn),血沉、C反應(yīng)蛋白水平、CD4+、CD8+水平以及血常規(guī)、肝功、腎功、凝血常規(guī)等觀察補(bǔ)脾益腸丸在潰瘍性結(jié)腸炎中的療效及安全性。研究所得數(shù)據(jù)采用SPSS15.0專業(yè)統(tǒng)計(jì)學(xué)軟件進(jìn)行分析檢驗(yàn)。結(jié)果:(1)兩組基線指標(biāo)各項(xiàng)數(shù)據(jù)、性別比例、病程、年齡、中醫(yī)證候積分比較無明顯統(tǒng)計(jì)學(xué)差異,(P0.05);(2)中醫(yī)證候療效比較:治療組為91.53%高于對照組的79.66%,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);(3)血沉、C反應(yīng)蛋白比較:治療后與治療前組內(nèi)比較血沉、C反應(yīng)蛋白均降低,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);治療后組間比較,治療組低于對照組,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);(4)治療后與治療前組內(nèi)比較:CD4+平均水平、CD8+平均水平均有顯著變化,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);治療后兩組間比較治療組CD4+低于對照組,CD8+高于對照組,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);(5)CD4+、CD8+治療前后數(shù)值變化值比較:治療組高于對照組,組間差異顯著,(P0.05);(6)腸鏡檢查黏膜病變療效比較:治療組總有效率為83.05%高于對照組的67.80%,統(tǒng)計(jì)學(xué)差異顯著,(P0.05);(7)安全性評(píng)價(jià):療程中治療組出現(xiàn)3例不良反應(yīng),對照組5例出現(xiàn)不良反應(yīng),經(jīng)對癥處理后癥狀改善。兩組均未出現(xiàn)明顯血常規(guī)、凝血、肝、腎功能異常。結(jié)論:補(bǔ)脾益腸丸對潰瘍性結(jié)腸炎的治療取得顯著成效,其治療內(nèi)在機(jī)制可能是通過對機(jī)體的CD4+、CD8+進(jìn)行調(diào)節(jié),修復(fù)受損潰瘍面,加速治愈疾病。
[Abstract]:Objective: To evaluate the therapeutic effect and safety of Bu PI Yichang pill in ulcerative colitis, and to lay a theoretical foundation for its use in ulcerative colitis. Methods: to select 118 cases of ulcerative colitis in Weifang city hospital in January 2015 and second people's Hospital in Weifang, Weifang City, Second People's hospital. Those who are in accordance with the diagnostic criteria of Western medicine have no fever and need to be treated for extra intestinal symptoms and systemic symptoms, and those with the exception of the sigmoid colon, except for other diseases, may affect the results of the study. Except for the hot toxic type of patients with the exception of the TCM diagnostic standard, all the patients are numbered 1-118 and the odd number is numbered. For the treatment group, the even number was the control group, with 59 cases in the treatment group and the control group. The control group was treated with 5 amino salicylic acid, and the treatment group was treated with the treatment of the acute symptom (TCM syndrome score less than 2 points) on the basis of the control group (the TCM syndrome score was less than 2 points) and the 1 course of treatment for 2 months. The treatment group completed the 2 course of treatment after the treatment. The curative effect and safety of the two groups were compared before and after treatment. The results were as follows: (1) the efficacy and safety of supplementing spleen Yichang pills in ulcerative colitis were observed. The results were as follows: the effect and safety of the spleen Yichang pill in ulcerative colitis. The results were as follows: (1) the results of the two groups were analyzed and tested. There was no significant difference between the two groups of baseline indicators, sex ratio, course of disease, age and TCM syndrome score, (P0.05); (2) the curative effect of TCM syndrome was compared: the treatment group was 91.53% higher than that of the control group (79.66%), the statistical difference was significant, (P0.05); (3) erythrocyte sedimentation rate, C reactive protein comparison: after treatment and before treatment group, C reactive protein was compared. Both decreased, statistical difference was significant (P0.05); compared with the control group after treatment, the treatment group was lower than the control group, with significant difference (P0.05); (4) the average level of CD4+ and the average level of CD8+ were significantly changed after treatment. The statistical difference was significant, (P0.05); the CD4+ in the treatment group was lower than the control group after treatment, and CD8+ was higher than that of the control group. CD8+ was higher than that of the control group. In the control group, the statistical difference was significant (P0.05); (5) the values of CD4+ and CD8+ were compared before and after the treatment: the treatment group was higher than the control group, and the difference between the groups was significant, (P0.05); (6) the curative effect of the colonoscopy was compared with the control group: the total effective rate of the treatment group was 83.05% higher than that of the control group, (P0.05); (7) the safety evaluation: treatment during the course of treatment. There were 3 cases of adverse reactions in the group, 5 cases in the control group had adverse reactions, and the symptoms improved after treatment. The two groups had no obvious blood routine, coagulation, liver and kidney function. Conclusion: the treatment of ulcerative colitis is remarkable. The internal mechanism of the treatment may be adjusted by the CD4+ and CD8+ of the body. Damage the ulcer surface and accelerate the cure of the disease.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張娜;趙和平;霍麗娟;;潰瘍性結(jié)腸炎治療進(jìn)展[J];中國藥物與臨床;2016年07期

2 李婷;高蕾;;益氣健脾活血法治療慢性復(fù)發(fā)型潰瘍性結(jié)腸炎[J];吉林中醫(yī)藥;2016年03期

3 羅書;李燕舞;;補(bǔ)中益氣丸對潰瘍性結(jié)腸炎小鼠的行為研究[J];陜西中醫(yī);2016年02期

4 丁宏輝;牟劍虹;;腸愈寧顆粒治療潰瘍性結(jié)腸炎的臨床療效觀察[J];中國生化藥物雜志;2015年11期

5 劉玉婷;郝微微;歷娜娜;溫紅珠;曹麗靜;史佳寧;;健脾化濕湯聯(lián)合清腸栓對脾虛濕熱型潰瘍性結(jié)腸炎患者生存質(zhì)量的影響[J];南京中醫(yī)藥大學(xué)學(xué)報(bào);2015年06期

6 高英杰;王英南;趙佛軍;姚芳;劉衛(wèi)民;;中藥保留灌腸加口服美沙拉嗪腸溶片對潰瘍性結(jié)腸炎患者血小板狀態(tài)的影響[J];中國老年學(xué)雜志;2015年19期

7 何麗娟;張軍東;安毛毛;姜遠(yuǎn)英;;腸道微生態(tài)與炎癥性腸病[J];藥學(xué)實(shí)踐雜志;2015年05期

8 明蘭;張?zhí)K閩;;生物制劑介入治療炎癥性腸病[J];胃腸病學(xué)和肝病學(xué)雜志;2015年09期

9 徐蒼福;;康復(fù)新液保留灌腸治療潰瘍性結(jié)腸炎的療效觀察[J];醫(yī)學(xué)理論與實(shí)踐;2015年17期

10 汪蕓;崔丁鹿;;潰瘍性結(jié)腸炎脾胃氣虛證的研究進(jìn)展[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2015年25期

相關(guān)碩士學(xué)位論文 前2條

1 韓珊子;潰瘍性結(jié)腸炎的中醫(yī)治療進(jìn)展[D];北京中醫(yī)藥大學(xué);2014年

2 胡豆豆;益氣健脾湯抗?jié)冃越Y(jié)腸炎（脾胃虛弱型）復(fù)發(fā)的臨床研究[D];山東中醫(yī)藥大學(xué);2011年

，

本文編號(hào)：1951591